share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  09/13 08:56

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc. has announced a series of significant corporate developments in recent filings with the SEC. On September 9, 2024, the company amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the potential sale of Placement Shares to $50 million. Additionally, on September 12, 2024, Allarity Therapeutics reported the resignation of Joan Y. Brown as Chief Financial Officer, effective immediately. Her departure was not due to any disagreements with the company's practices or policies. On the same day, the company's Board of Directors appointed Alexander Epshinsky as the new CFO. Epshinsky, a seasoned finance professional with experience in the pharmaceutical and biotech sectors, has entered into an Employment Agreement with Allarity Therapeutics, which includes a $340,000 annual base salary, potential performance-based increases, equity in the form of restricted stock units, and eligibility for annual bonuses, among other benefits. The company has also indicated a renewed focus on financing strategies to support its operational and strategic goals following the recent changes in management.
Allarity Therapeutics, Inc. has announced a series of significant corporate developments in recent filings with the SEC. On September 9, 2024, the company amended its At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC, increasing the potential sale of Placement Shares to $50 million. Additionally, on September 12, 2024, Allarity Therapeutics reported the resignation of Joan Y. Brown as Chief Financial Officer, effective immediately. Her departure was not due to any disagreements with the company's practices or policies. On the same day, the company's Board of Directors appointed Alexander Epshinsky as the new CFO. Epshinsky, a seasoned finance professional with experience in the pharmaceutical and biotech sectors, has entered into an Employment Agreement with Allarity Therapeutics, which includes a $340,000 annual base salary, potential performance-based increases, equity in the form of restricted stock units, and eligibility for annual bonuses, among other benefits. The company has also indicated a renewed focus on financing strategies to support its operational and strategic goals following the recent changes in management.
Allarity Therapeutics， Inc.在最近向SEC提交的文件中宣布了一系列重大企业发展。2024年9月9日，该公司修订了与Ascendiant Capital Markets， LLC的现场发行销售协议，将可售股票增加到5000万美元。此外，2024年9月12日，Allarity Therapeutics报告了首席财务官约翰·Y·布朗的辞职，立即生效。她的离职不是由于与公司的做法或政策有任何分歧。同一天，公司董事会任命了亚历山大·埃普辛斯基为新任首席财务官。埃普辛斯基是一位经验丰富的金融专业人士，具有制药和生物技术领域的经验，与Allarity Therapeutics达成了就业协议，包括34万美元的年度基本工资，潜在的绩效奖励，以限制股票单位的形式提供的股权以及有资格获得年度奖金等其他福利。公司还表示，在近期管理层变动后，将重新关注为支持其运营和战略目标的融资策略。
Allarity Therapeutics， Inc.在最近向SEC提交的文件中宣布了一系列重大企业发展。2024年9月9日，该公司修订了与Ascendiant Capital Markets， LLC的现场发行销售协议，将可售股票增加到5000万美元。此外，2024年9月12日，Allarity Therapeutics报告了首席财务官约翰·Y·布朗的辞职，立即生效。她的离职不是由于与公司的做法或政策有任何分歧。同一天，公司董事会任命了亚历山大·埃普辛斯基为新任首席财务官。埃普辛斯基是一位经验丰富的金融专业人士，具有制药和生物技术领域的经验，与Allarity Therapeutics达成了就业协议，包括34万美元的年度基本工资，潜在的绩效奖励，以限制股票单位的形式提供的股权以及有资格获得年度奖金等其他福利。公司还表示，在近期管理层变动后，将重新关注为支持其运营和战略目标的融资策略。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间